Clinical Trials Logo
  1. Home
  2. B-cell Lymphoma Refractory
  3. NCT04303247

CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

B-cell Lymphoma Refractory Clinical Trial

Official title:
CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL: a Multi-center, Uncontrolled Trial.

Clinical Trial Summary

Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. There are patients who resisted anti-CD19 CAR-T cells or with CD19 negative relapse. To make further improvement, combining CD19 and CD22 as dual-targets for CAR-T cells, which adapt the FasT CAR-T cells manufacture technology to shorten the manufacture time and maintain the stemness of CAR-T cells. We launch such a clinical trial using CD19 and CD22 targeted CAR-T cells for patients with relapsed and refractory B-cell NHL to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cell therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04303247
Study type Interventional
Source Xinqiao Hospital of Chongqing
Contact Xi Zhang, MD phD
Phone 13808310064
Email zhangxxi@sina.com
Status Not yet recruiting
Phase Early Phase 1
Start date May 1, 2020
Completion date May 1, 2023
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05645744 - Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Active, not recruiting NCT03664635 - MB-CART20.1 Lymphoma Phase 1/Phase 2
Recruiting NCT03853616 - MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) Phase 1/Phase 2
Recruiting NCT05360238 - Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL Phase 1/Phase 2
Recruiting NCT05318963 - Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma Phase 1
Active, not recruiting NCT04531046 - Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation Phase 2
Not yet recruiting NCT05705570 - A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies Phase 1
Active, not recruiting NCT04304040 - A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma Phase 1/Phase 2
Not yet recruiting NCT05909098 - Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma Phase 1/Phase 2
Recruiting NCT04747093 - Induced-T Cell Like NK Cells for B Cell Malignancies Phase 1/Phase 2
Completed NCT05130489 - CAR T Cell Therapy Related Cardiovascular Outcomes
Recruiting NCT01786018 - Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas Phase 2
Recruiting NCT06220097 - Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies Phase 2
Active, not recruiting NCT04214886 - CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies Phase 1
Completed NCT01535989 - Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma Phase 1